Trial · NCT07877194
A Clinical Study of Ivonescimab in Combination With Cadonilimab or Ipilimumab for Advanced Renal Cancer
NCT07877194, Phase 2, Not yet recruiting, Summit Therapeutics
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Clinical Study of Ivonescimab in Combination With Cadonilimab or Ipilimumab for Advanced Renal Cancer. Trials, record NCT07877194. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07877194
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Clinical Study of Ivonescimab in Combination With Cadonilimab or Ipilimumab for Advanced Renal Cancer
- NCT number
- NCT07877194
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 100 participants, estimated
- Lead sponsor
- Summit Therapeutics
- Conditions
- Renal Cell Carcinoma, Clear Cell
- Interventions
- Ivonescimab (dose level 1) combined with Cadonilimab, Ivonescimab (dose level 2) combined with Cadonilimab, Ivonescimab combined with Ipilimumab, Ivonescimab, Nivolumab combined with Ipilimumab
- First posted
- 2026-10-16
- Last updated
- 2026-10-16
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Objective Response Rate (ORR) | From randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years. | ORR per RECIST v1.1 by investigator |
| Primary | Adverse Events (AEs) | At the time of initiation of the first dose through 90 days after the last dose of study treatment. | Adverse events (AEs) as characterized by type, incidence, severity, seriousness, and relationship to study treatment |
| Secondary | Disease Control Rate (DCR) | From randomization to first occurrence of disease progression, death or study completion, whichever came first, assessed up to 3 years. | DCR assessed by investigator according to RECIST v1.1. |
| Secondary | Duration of Response (DoR) | From time of first recorded response randomization to progressive disease, or death or study completion, whichever came first, assessed up to 3 years. | Duration of response (DoR) assessed by investigator according to RECIST v1.1. |
| Secondary | Progression Free Survival (PFS) | From randomization to progressive disease or death, whichever came first, assessed up to 3 years. | Progression Free Survival (PFS) is defined as the time from randomization to the first documented disease progression (per RECIST v1.1) assessed by investigator or death due to any cause, whichever occurs first. |
| Secondary | Overall Survival (OS) | From randomization to death, assessed up to 4 years. | Overall Survival (OS) is defined as the time from randomization to death due to any cause. |
| Secondary | Pharmacokinetics (PK) | From first dose of study drug until end of treatment, assessed up to 3 years. | Serum drug concentration at different time points after administration |
| Secondary | Anti-Drug Antibodies (ADA) | From time of initiation of first dose to 30 days after end of treatment. | Number of subjects with detectable anti-drug antibodies (ADA). |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07877194
GET https://conductscience.org/api/trials/v1/NCT07877194/registered